Literature DB >> 32975643

"I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.

Adrianne R Mallen1,2, Claire C Conley3,4, Lindsay Fuzzell3, Dana Ketcher3, Bianca M Augusto3, McKenzie McIntyre3, Laura V Barton5, Mary K Townsend6, Brooke L Fridley7, Shelley S Tworoger6, Robert M Wenham1, Susan T Vadaparampil8.   

Abstract

OBJECTIVE: Identify predisposing, enabling, and reinforcing factors impacting genetic counseling/testing among ovarian cancer patients guided by Green and Kreuter's PRECEDE-PROCEED model.
METHODS: Gynecologic oncology providers (N = 4), genetic counselors (N = 4), and ovarian cancer patients (N = 9) completed semi-structured qualitative interviews exploring participants' knowledge of and experiences with genetic counseling/testing. Interviews were audio recorded, transcribed verbatim, and analyzed using inductive content analysis by two independent raters.
RESULTS: Thematic analysis identified predisposing, enabling, and reinforcing factors impacting referral for and uptake of genetic counseling/testing. Predisposing factors included participant's knowledge, beliefs, and attitudes related to genetic counseling/testing. Both patients and providers also cited that insurance coverage and out-of-pocket cost are major concerns for ovarian cancer patients considering genetic testing. Finally, both patients and providers emphasized that genetic counseling/testing would provide additional information to an ovarian cancer patient. While providers emphasized that genetic testing results were useful for informing a patient's personal treatment plan, patients emphasized that this knowledge would be beneficial for their family members.
CONCLUSION: Barriers to genetic testing for ovarian cancer patients exist at multiple levels, including the patient (e.g., knowledge, attitudes), the provider (e.g., workload, availability of services), the institution (e.g., difficulty with referrals/scheduling), and the healthcare system (e.g., insurance/cost). Interventions aiming to increase genetic testing among ovarian cancer patients will likely need to target multiple levels of influence. Future quantitative studies are needed to replicate these results. This line of work will inform specific multilevel intervention strategies that are adaptable to different practice settings, ultimately improving guideline concordant care.

Entities:  

Keywords:  BRCA1/2; Genetic counseling; Ovarian cancer; genetic testing

Mesh:

Year:  2020        PMID: 32975643      PMCID: PMC7981241          DOI: 10.1007/s00520-020-05779-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  42 in total

1.  Qualitative research methods: when to use them and how to judge them.

Authors:  K Hammarberg; M Kirkman; S de Lacey
Journal:  Hum Reprod       Date:  2016-01-11       Impact factor: 6.918

2.  A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.

Authors:  Erica M Bednar; Holly D Oakley; Charlotte C Sun; Catherine C Burke; Mark F Munsell; Shannon N Westin; Karen H Lu
Journal:  Gynecol Oncol       Date:  2017-06-10       Impact factor: 5.482

3.  An Applied Framework in Support of Shared Decision Making about BRCA Genetic Testing.

Authors:  Thomas B Silverman; Gilad J Kuperman; Alejandro Vanegas; Margaret Sin; Jill Dimond; Katherine D Crew; Rita Kukafka
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

4.  Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.

Authors:  Margaret I Liang; Deanna H Wong; Christine S Walsh; Robin Farias-Eisner; Joshua G Cohen
Journal:  J Genet Couns       Date:  2017-08-07       Impact factor: 2.537

5.  Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper.

Authors:  Leslie M Randall; Bhavana Pothuri; Elizabeth M Swisher; John P Diaz; Adam Buchanan; Catherine T Witkop; C Bethan Powell; Ellen Blair Smith; Mark E Robson; Jeff Boyd; Robert L Coleman; Karen Lu
Journal:  Gynecol Oncol       Date:  2017-06-07       Impact factor: 5.482

6.  Experiences of genetic counseling for BRCA1/2 among recently diagnosed breast cancer patients: a qualitative inquiry.

Authors:  Susan T Vadaparampil; Gwendolyn Pickard Quinn; Jennifer Brzosowicz; Cheryl A Miree
Journal:  J Psychosoc Oncol       Date:  2008

7.  Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients.

Authors:  Susan T Vadaparampil; Gwendolyn P Quinn; Cheryl A Miree; Jennifer Brzosowicz; Bradford Carter; Christine Laronga
Journal:  Ann Surg Oncol       Date:  2009-04-30       Impact factor: 5.344

8.  Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida.

Authors:  S T Vadaparampil; C L Scherr; D Cragun; T L Malo; T Pal
Journal:  Clin Genet       Date:  2014-05-09       Impact factor: 4.438

9.  Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.

Authors:  Panagiotis A Konstantinopoulos; Barbara Norquist; Christina Lacchetti; Deborah Armstrong; Rachel N Grisham; Paul J Goodfellow; Elise C Kohn; Douglas A Levine; Joyce F Liu; Karen H Lu; Dorinda Sparacio; Christina M Annunziata
Journal:  J Clin Oncol       Date:  2020-01-27       Impact factor: 44.544

10.  A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.

Authors:  Heather Hampel; Robin L Bennett; Adam Buchanan; Rachel Pearlman; Georgia L Wiesner
Journal:  Genet Med       Date:  2014-11-13       Impact factor: 8.822

View more
  2 in total

1.  Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study.

Authors:  Claire C Conley; McKenzie McIntyre; Nicole A Pensak; Filipa Lynce; Deena Graham; Roohi Ismail-Khan; Katherine Lopez; Susan T Vadaparampil; Suzanne C O'Neill
Journal:  Breast Cancer Res Treat       Date:  2022-01-07       Impact factor: 4.872

2.  Provider discussion of genetic counseling among high-risk Spanish-preferring Latina breast cancer survivors.

Authors:  Claire C Conley; Jessica N Rivera Rivera; Eida M Castro-Figueroa; Laura Moreno; Julie Dutil; Jennifer D García; Charité Ricker; Gwendolyn P Quinn; Hatem Soliman; Susan T Vadaparampil
Journal:  Transl Behav Med       Date:  2022-10-07       Impact factor: 3.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.